Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2016

View Archived Issues

Laboratorios del Dr. Esteve reports sigma1 and mu-opioid receptor ligands

Biorhythm patents L. plantarum strain to treat allergy

Igenica Biotherapeutics presents antineoplastic compounds

Aquinnah Pharmaceuticals reports TAR DNA-binding protein inhibitors

Prana Biotechnology divulges compounds for neurological disorders

Phase I results for new generation fluoroquinolone lascufloxacin

Arsanis MAbs target the LPS-O antigen of Klebsiella pneumoniae ST258

FDA approves Humira for intermediate, posterior and panuveitis

Positive opinion handed down for Belkyra through European decentralized procedure

European and Japanese approvals for Kyprolis in multiple myeloma

Lilly's ixekizumab approved in Japan

New aminomethylcycline shows efficacy in pneumonia murine models

BIND Therapeutics files motion for court approval of Pfizer stalking horse asset purchase agreement

Argenx reports promising initial results from multiple-ascending-dose phase I study of ARGX-113

Takeda files for Japanese approval of ixazomib for relapsed or refractory multiple myeloma

Vimpat approved in Japan as adjunctive therapy to treat partial onset seizures

Phase I results support further development of RE-024 for the potential treatment of PKAN

Soricimed Biopharma's SOR-C13 receives FDA orphan drug designation

Japan first to approve Lumicef worldwide

Evofosfamide in combination with sorafenib shows preliminary efficacy for HCC

PhaseBio initiates phase IIa trial of PB-1046 in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...